TSE:TST Telesta Therapeutics (TST) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Telesta Therapeutics Stock (TSE:TST) Get Telesta Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume292,300 shsAverage Volume212,584 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telesta Therapeutics Inc. is a human therapeutics company. The Company is a biotechnology company, which is focused on the licensing/acquisition and development of transformational therapeutics for the treatment of human diseases, such as cancer, immune diseases and targeted rare diseases. The Company focuses on developing drug candidate, Mycobacterium phlei cell wall-nucleic acid complex (MCNA) for the treatment of non-muscle invasive bladder cancer. The Company owns a manufacturing facility for MCNA at Montreal, Quebec. The Company has not generated any revenues. Read More Receive TST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TST Stock News HeadlinesTranscenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic CancerMarch 30, 2023 | markets.businessinsider.comSeelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of TodayMarch 16, 2023 | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 4 at 1:00 AM | InvestorPlace (Ad)Minnesota launches telehealth program to offer no-cost COVID-19 therapeuticsDecember 19, 2022 | msn.comTelo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical StudySeptember 15, 2022 | finance.yahoo.comDr. B Raises $8 Million for New Telehealth Service Making Prescription Medications Affordable & Accessible for AnyoneAugust 16, 2022 | finance.yahoo.comTrelica Named 'Leader' and 'Outperformer' in GigaOm's SaaS Management Platforms Radar ReportJuly 14, 2022 | finance.yahoo.comTessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022June 13, 2022 | finance.yahoo.comSee More Headlines TST Stock Analysis - Frequently Asked Questions How do I buy shares of Telesta Therapeutics? Shares of TST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Telesta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesta Therapeutics investors own include Bombardier, Inc. Class B (BBD.B), Big Banc Split (BNK), KalVista Pharmaceuticals (KALV), ProMetic Life Sciences (PLI) and Petrowest (PRW). Industry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:TST CIKN/A Webwww.telestatherapeutics.com Phone+1-514-5876148FaxN/AEmployees147,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (TSE:TST) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersOnly one company survived this screenOn May 21, 2026, a federal board voted unanimously to lend one gold company roughly $3 billion. The company...Behind the Markets | SponsoredThe Market Hasn't Fully Caught This YetSurface samples on this project have returned grades up to 73 g/t gold and 21% copper, right next to a produce...i2i Marketing Group, LLC | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredPass by August 7… or wait until 2027?Right now, the Clarity Act is working through Washington. And if it passes, banks, asset managers, and payment...Crypto 101 Media | Sponsored7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredExecutive order could send gold to 6,000 per ounceExecutive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...Cedar Gold Group | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored[URGENT] Mode Mobile terms changing Aug 14Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesta Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesta Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.